These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 34571905)

  • 1. The Interplay between Glioblastoma and Its Microenvironment.
    Dapash M; Hou D; Castro B; Lee-Chang C; Lesniak MS
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
    Feldman L
    Front Immunol; 2024; 15():1384249. PubMed ID: 38994360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
    Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
    Front Immunol; 2020; 11():582106. PubMed ID: 33178210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
    Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
    J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
    Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
    PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophages and microglia: the cerberus of glioblastoma.
    Buonfiglioli A; Hambardzumyan D
    Acta Neuropathol Commun; 2021 Mar; 9(1):54. PubMed ID: 33766119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
    DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
    Front Immunol; 2020; 11():1402. PubMed ID: 32765498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics.
    Ye Z; Ai X; Zhao L; Fei F; Wang P; Zhou S
    Oncogene; 2021 Oct; 40(42):6059-6070. PubMed ID: 34556813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
    Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
    Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
    Kamran N; Chandran M; Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas.
    Huang S; Song Z; Zhang T; He X; Huang K; Zhang Q; Shen J; Pan J
    Front Immunol; 2020; 11():585034. PubMed ID: 33193404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune landscapes associated with different glioblastoma molecular subtypes.
    Martinez-Lage M; Lynch TM; Bi Y; Cocito C; Way GP; Pal S; Haller J; Yan RE; Ziober A; Nguyen A; Kandpal M; O'Rourke DM; Greenfield JP; Greene CS; Davuluri RV; Dahmane N
    Acta Neuropathol Commun; 2019 Nov; 7(1):203. PubMed ID: 31815646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment.
    Mu Y; Zhang Z; Zhou H; Ma L; Wang DA
    Biomater Sci; 2024 Aug; 12(16):4045-4064. PubMed ID: 38993162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements.
    Fei X; Wu J; Tian H; Jiang D; Chen H; Yan K; Wang Y; Zhao Y; Chen H; Xie X; Wang Z; Zhu W; Huang Q
    Cancer Biomark; 2024; 41(1):1-24. PubMed ID: 39240627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.
    Tomaszewski W; Sanchez-Perez L; Gajewski TF; Sampson JH
    Clin Cancer Res; 2019 Jul; 25(14):4202-4210. PubMed ID: 30804019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
    Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
    Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
    Zhang B; Shen R; Cheng S; Feng L
    Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment.
    Hernández A; Domènech M; Muñoz-Mármol AM; Carrato C; Balana C
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastoma-activated pericytes support tumor growth via immunosuppression.
    Sena IFG; Paiva AE; Prazeres PHDM; Azevedo PO; Lousado L; Bhutia SK; Salmina AB; Mintz A; Birbrair A
    Cancer Med; 2018 Apr; 7(4):1232-1239. PubMed ID: 29479841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.